International biotechnology company Bavarian Nordic announced on Thursday that is has given the first human an Ebola vaccine booster to study the response of the drug.
Bavarian Nordic said the subject was dosed with the MVA-BN Filo during the first phase of the trial. The trial is sponsored by the University of Oxford. The MVA-BN booster vaccine is being studied along with another Ebola vaccine that was developed by GlaxoSmithKline and the U.S. National Institute of Allergy and Infectious Diseases. The vaccine is designed to fight off the Ebola Zaire, Ebola Sudan and Marburg virus.
Studies have found the MVA booster dose may cause the vaccine to offer a more “robust and durable immune response, the company said. Clinical trials will look to replicate the findings in the studies.
The company will enroll 60 healthy adults divided into three groups each receiving a different dose of the Ebola vaccine. Half of the participants in each group will also receive the booster dose of the MVA-BN Filo vaccine.
Paul Chaplin, president and CEO of Bavarian Nordic, said the trials are part of the fast-track development of a vaccine against a virus.
“We are also making progress in our collaboration with Janssen as part of their commitment to accelerate and expand the production of its Ebola vaccine regimen. Manufacturing of our MVA-BN Filo vaccine is well underway, and the first trial in humans of this prime-boost vaccine regimen will soon open for enrollment.”